Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Matthew Sikora to Breast Neoplasms

This is a "connection" page, showing publications Matthew Sikora has written about Breast Neoplasms.

 
Connection Strength
  
 
 
2.522
  
  1. Sottnik JL, Shackleford MT, Robinson SK, Villagomez FR, Bahnassy S, Oesterreich S, Hu J, Madak-Erdogan Z, Riggins RB, Corr BR, Cook LS, Trevi?o LS, Bitler BG, Sikora MJ. WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers. Cancer Res Commun. 2024 01 17; 4(1):134-151.
    View in: PubMed
    Score: 0.372
  2. Sottnik JL, Bordeaux EK, Mehrotra S, Ferrara SE, Goodspeed AE, Costello JC, Sikora MJ. Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast. Mol Cancer Res. 2021 08; 19(8):1270-1282.
    View in: PubMed
    Score: 0.308
  3. Sikora MJ, Jacobsen BM, Levine K, Chen J, Davidson NE, Lee AV, Alexander CM, Oesterreich S. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Res. 2016 09 20; 18(1):92.
    View in: PubMed
    Score: 0.224
  4. Sikora MJ, Jankowitz RC, Dabbs DJ, Oesterreich S. Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems. Steroids. 2013 Jun; 78(6):568-75.
    View in: PubMed
    Score: 0.172
  5. Sikora MJ, Strumba V, Lippman ME, Johnson MD, Rae JM. Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. Breast Cancer Res Treat. 2012 Aug; 134(3):1027-39.
    View in: PubMed
    Score: 0.164
  6. Sikora MJ, Rae JM, Johnson MD, Desta Z. Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth. HIV Med. 2010 Oct 01; 11(9):603-7.
    View in: PubMed
    Score: 0.145
  7. Sikora MJ, Cordero KE, Larios JM, Johnson MD, Lippman ME, Rae JM. The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat. 2009 May; 115(2):289-96.
    View in: PubMed
    Score: 0.126
  8. Ding K, Chen L, Levine KM, Sikora MJ, Tasdemir N, Dabbs D, Jankowitz R, Hazan R, Shah O, Atkinson J, Lee AV, Oesterreich S. FGFR4 in endocrine resistance: overexpression and estrogen regulation without direct causative role. Breast Cancer Res Treat. 2025 Jun; 211(2):501-515.
    View in: PubMed
    Score: 0.101
  9. Li Z, Li T, Yates ME, Wu Y, Ferber A, Chen L, Brown DD, Carroll JS, Sikora MJ, Tseng GC, Oesterreich S, Lee AV. The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer. Cancer Res. 2023 08 15; 83(16):2656-2674.
    View in: PubMed
    Score: 0.090
  10. Bahnassy S, Sikora MJ, Riggins RB. Unlocking the Mysteries of Lobular Breast Cancer Biology Needs the Right Combination of Preclinical Models. Mol Cancer Res. 2022 06 03; 20(6):837-840.
    View in: PubMed
    Score: 0.083
  11. Pitzer LM, Moroney MR, Nokoff NJ, Sikora MJ. WNT4 Balances Development vs Disease in Gynecologic Tissues and Women's Health. Endocrinology. 2021 07 01; 162(7).
    View in: PubMed
    Score: 0.078
  12. Sreekumar S, Levine KM, Sikora MJ, Chen J, Tasdemir N, Carter D, Dabbs DJ, Meier C, Basudan A, Boone D, McAuliffe PF, Jankowitz RC, Lee AV, Atkinson JM, Oesterreich S. Differential Regulation and Targeting of Estrogen Receptor a Turnover in Invasive Lobular Breast Carcinoma. Endocrinology. 2020 09 01; 161(9).
    View in: PubMed
    Score: 0.074
  13. Cao L, Basudan A, Sikora MJ, Bahreini A, Tasdemir N, Levine KM, Jankowitz RC, McAuliffe PF, Dabbs D, Haupt S, Haupt Y, Lucas PC, Lee AV, Oesterreich S, Atkinson JM. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. Cancer Lett. 2019 Oct 01; 461:21-30.
    View in: PubMed
    Score: 0.068
  14. Bossart EA, Tasdemir N, Sikora MJ, Bahreini A, Levine KM, Chen J, Basudan A, Jacobsen BM, Burns TF, Oesterreich S. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma. Breast Cancer Res Treat. 2019 Jun; 175(2):327-337.
    View in: PubMed
    Score: 0.066
  15. Tasdemir N, Bossart EA, Li Z, Zhu L, Sikora MJ, Levine KM, Jacobsen BM, Tseng GC, Davidson NE, Oesterreich S. Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. Cancer Res. 2018 11 01; 78(21):6209-6222.
    View in: PubMed
    Score: 0.064
  16. Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, Gellert P, Buluwela L, Harrod A, Thornhill A, Nikitorowicz-Buniak J, Bhamra A, Turgeon MO, Poulogiannis G, Gao Q, Martins V, Hills M, Garcia-Murillas I, Fribbens C, Patani N, Li Z, Sikora MJ, Turner N, Zwart W, Oesterreich S, Carroll J, Ali S, Dowsett M. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat Commun. 2017 11 30; 8(1):1865.
    View in: PubMed
    Score: 0.061
  17. Hertz DL, Kidwell KM, Hilsenbeck SG, Oesterreich S, Osborne CK, Philips S, Chenault C, Hartmaier RJ, Skaar TC, Sikora MJ, Rae JM. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat. 2017 Nov; 166(1):277-287.
    View in: PubMed
    Score: 0.059
  18. Sikora MJ, Johnson MD, Lee AV, Oesterreich S. Endocrine Response Phenotypes Are Altered by Charcoal-Stripped Serum Variability. Endocrinology. 2016 Oct; 157(10):3760-3766.
    View in: PubMed
    Score: 0.055
  19. Dennison JB, Shahmoradgoli M, Liu W, Ju Z, Meric-Bernstam F, Perou CM, Sahin AA, Welm A, Oesterreich S, Sikora MJ, Brown RE, Mills GB. High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clin Cancer Res. 2016 Oct 15; 22(20):5068-5078.
    View in: PubMed
    Score: 0.055
  20. Capper CP, Larios JM, Sikora MJ, Johnson MD, Rae JM. The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer. Breast Cancer Res Treat. 2016 05; 157(1):23-30.
    View in: PubMed
    Score: 0.054
  21. Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res. 2014 Mar 01; 74(5):1463-74.
    View in: PubMed
    Score: 0.046
  22. Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar TC, Nguyen AT, Desta Z, Storniolo AM, Flockhart DA, Hayes DF, Stearns V. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J. 2009 Aug; 9(4):258-64.
    View in: PubMed
    Score: 0.034
  23. Du T, Sikora MJ, Levine KM, Tasdemir N, Riggins RB, Wendell SG, Van Houten B, Oesterreich S. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Res. 2018 09 04; 20(1):106.
    View in: PubMed
    Score: 0.016
  24. Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat. 2009 Oct; 117(3):571-5.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)